TCGA-K4-A6MB-01A-11R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.40735874
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.220
- G2M_CHECKPOINT+0.220
- E2F_TARGETS+0.210
- MITOTIC_SPINDLE+0.210
- APICAL_SURFACE+0.140
- ESTROGEN_RESPONSE_EARLY+0.130
- PROTEIN_SECRETION+0.120
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.100
- SPERMATOGENESIS+0.080
- KRAS_SIGNALING_DN+0.070
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.680
- INTERFERON_GAMMA_RESPONSE-0.590
- ALLOGRAFT_REJECTION-0.520
- IL6_JAK_STAT3_SIGNALING-0.420
- INFLAMMATORY_RESPONSE-0.410
- TNFA_SIGNALING_VIA_NFKB-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- HYPOXIA-0.360
- COMPLEMENT-0.320
- PANCREAS_BETA_CELLS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3bc40056-88b6-483c-8701-747eb6e851c4 | — | — | 0.835 |
| 2 | TCGA-A7-A4SB-01A-21R-A266-07 | — | B | 0.795 |
| 3 | C3N-03222 | — | cohortA4 | 0.792 |
| 4 | MBCProject_6127_T1_RNA | — | B | 0.789 |
| 5 | TCGA-XF-AAMX-01A-11R-A42T-07 | — | — | 0.787 |
| 6 | MDT-AP-1367 | Med | Medulloblastoma | 0.780 |
| 7 | TCGA-A8-A08O-01A-21R-A056-07 | — | B | 0.779 |
| 8 | 3f4020bf-9f9a-479d-b3af-883c5875d84e | — | — | 0.774 |
| 9 | TCGA-BH-A1EV-01A-11R-A137-07 | — | C | 0.769 |
| 10 | TCGA-D8-A1XD-01A-11R-A14D-07 | — | B | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| MYOGENESIS | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |